Malaria as a disease of the poorest in the world is on the global agenda. Many different groups take efforts in order to tackle malaria. Facing the fact that mainly children and pregnant women present the biggest problems it is difficult to maintain a logical way in order to improve the malaria situation. Therefore, organization and coordination of the efforts is an area of improvement. For example, various Public Private Partnerships have partly identical missions (e.g. GAVI and MVI), and there is good reason for combining their efforts and save administrative resources.
The first step in a logic chain should be to provide better diagnostic features for the correct detection of malaria with the consequence of an adequate treatment. Country surveillance programs need to be set up in order follow resistance patterns, treatment effects, demographic patterns etc. In parallel better therapeutic and preventive measures need to be developed in order to win the race against resistance of vectors as well as parasites.
All these efforts need to be planned, coordinated, managed and regulated. This requests one global coordinator with an “umbrella function” that defines rules for all partners involved and manages the cooperation. The umbrella function should sit within a non-profit organization with long-term experience in the field, in other words the UN and more precisely the WHO. Cooperating partners can be of very different origins like industry, governments, private and public foundations, NGOs, etc. Many of these organizations already exist, but their efforts are partly the same, some themes are left out the scope. Therefore, the general recommendation would be to better streamline existing initiatives, partly redefine their mission and vision and make optimal use of existing resources.
Table of Contents
2. INTRODUCTION
2.1 HUMAN MALARIA
2.1.1 Causative Parasites and their Life Cycle
2.1.2 Clinical Signs and Symptoms
2.1.2.1 General Clinical Features
2.1.2.2 Severe Falciparum Malaria
2.1.3 Diagnosis
2.1.4 Laboratory Findings
2.2 HISTORY
2.2.1 History of the Human Malaria Parasites
2.2.2 Geographical Malaria History
2.2.3 History of Malaria Handling
2.3 EPIDEMIOLOGY
2.3.1 Malaria Transmission
2.3.2 Prevalence and Incidence
2.3.3 Endemicity
2.3.3.1 Stable Endemic Malaria
2.3.3.2 Unstable and Epidemic Malaria
2.3.4 Epidemic preparedness, prediction and prevention of epidemics
2.3.5 Epidemiological information systems
2.3.6 Resistance Pattern
2.3.7 Travelers
2.4 MALARIA IN THE PEDIATRIC POPULATION AND PREGNANT WOMEN
2.4.1 Pediatric Population
2.4.2 Pregnant Women
2.5 MALARIA AS A DISEASE OF THE POOR
3. GLOBAL MALARIA CONTROL STRATEGIES
3.1 PREVENTIVE MEASURES
3.1.1 History of the Global Malaria Control Strategies
3.1.2 General preventative Measures
3.1.3 Vector Control
3.1.3.1 Insect repellents
3.1.3.2 Insecticide treated nets (ITNs)
3.1.3.3 Indoor Residual Spraying
3.1.3.4 Recommendations
3.1.4 Chemo-Prophylaxis
3.1.5 Vaccination
3.1.6 Other Preventive Measures
3.2 CURRENT TREATMENT APPROACHES
3.2.1 Benefits and Liabilities of Existing Anti-Malarial Drugs
3.2.1.1 Quinolines
3.2.1.2 Artemisinins
3.2.1.3 Antifolates
3.2.1.4 Antibiotics
3.2.2 Combination Therapy
3.3 TREATMENT POLICIES AND PRACTICES
3.4 MALARIA PREVENTION AND TREATMENT IN PREGNANT WOMEN
4. GLOBAL PUBLIC INITIATIVES – PUBLIC PRIVATE PARTNERSHIPS
4.1 WORLD HEALTH ORGANIZATION (WHO)
4.1.1 WHO Interactions with NGOs
4.1.2 WHO Essential Drugs
4.1.3 WHO and the Private Sector / Public Private Partnerships (PPPs)
4.2 SPECIAL PROGRAM FOR RESEARCH AND TRAINING IN TROPICAL DISEASES (TDR)
4.3 MEDICINES FOR MALARIA VENTURE (MMV)
4.4 ROLL BACK MALARIA (RBM)
4.5 GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION (GAVI)
4.6 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND MALARIA VACCINE INITIATIVE (MVI)
4.7 WORLD BANK
4.8 BILL & MELINDA GATES FOUNDATION AS AN EXAMPLE FOR PRIVATE FOUNDATIONS
4.9 DONATION-DISTRIBUTION PARTNERSHIPS
5. HEALTH ECONOMY
5.1 MALARIA ASSOCIATED ECONOMIC MEASURES
5.2 COSTS OF ANTI-MALARIAL DRUGS
5.3 FINANCING OF ANTI-MALARIAL DRUGS
5.4 REGULATORY AGENCIES’ CONTRIBUTIONS
5.4.1 Orphan Drugs
5.4.2. Pediatric Laws
5.4.3 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
5.5 PHARMACEUTICAL INDUSTRY
5.5.1 Overview on Development of New Drugs
5.5.2 Development of New Anti-malarial Drugs
5.5.3 Glaxo Smith Kline (GSK)
6. DISCUSSION
6.1 THE CHALLENGE OF MALARIA IN ENDEMIC COUNTRIES
6.2 ROLE OF THE ENDEMIC COUNTRIES
6.3 PUBLIC-PRIVATE PARTNERSHIPS (PPPS)
7. CONCLUSION
Research Objectives and Themes
This thesis examines the global challenge of malaria, focusing on the epidemiological, economic, and political factors that hinder control in endemic countries. It explores the failures of past eradication efforts, the impact of drug resistance, and the critical role of Public-Private Partnerships (PPPs) in facilitating the development and equitable distribution of effective, affordable anti-malarial treatments and vaccines.
- Epidemiology and transmission dynamics of malaria parasites.
- Clinical manifestations and treatment complications in vulnerable populations.
- Evaluation of global public health control strategies and preventive measures.
- Economic analysis of the malaria burden and healthcare financing models.
- The impact and future potential of Public-Private Partnerships in pharmaceutical innovation.
Excerpt from the Book
2.1.1 Causative Parasites and their Life Cycle
Malaria is a protozoan disease transmitted by the bite of Anopheles mosquitoes. It is the most important parasitic disease in humans. Four species of the genus Plasmodium infect humans: • P. falciparum • P. malariae • P. vivax • P. ovale.
Recently, a fifth species has been found to be causative for human malaria: P. knowlesi which was previously thought to be infective in long-tailed macaque monkeys only. Obviously, P. knowlesi infections have been wrongly diagnosed as P. malariae malaria. Further work is needed to determine whether human P. knowlesi infections are acquired from macaque monkeys or whether a host switch to human beings has occured [107].
Among the four well-known species of human malaria, P. falciparum stands out as the most malignant form and the only one where severe complications such as cerebral malaria, severe anemia, renal failure and pulmonary affection are frequently seen. Some features, important for disease severity and pathogenesis, separate P. falciparum from the other human malarias: the ability to invade erythrocytes of all ages causing very high parasitemias, enhanced growth and the capacity to adhere to vascular endothelium through the process of sequestration. The infected erythrocyte can adhere to the endothelium and to uninfected erythrocytes via parasite-derived proteins expressed on the surface of the infected erythrocyte. This enables the parasite to avoid clearance by the immune system in the spleen. The adherence causes a considerable obstruction to tissue perfusion. The destruction of the red blood cells is an inevitable part of falciparum malaria [42], [64].
Summary of Chapters
2. INTRODUCTION: Provides an overview of the history, epidemiology, and global health burden of malaria, highlighting the persistence of the disease and the failure of past eradication programs.
3. GLOBAL MALARIA CONTROL STRATEGIES: Discusses preventive measures and current treatment protocols, emphasizing the necessity of combination therapies and the integration of these strategies into healthcare systems.
4. GLOBAL PUBLIC INITIATIVES – PUBLIC PRIVATE PARTNERSHIPS: Analyzes the emergence and functionality of various global health initiatives and partnerships, such as WHO, TDR, MMV, and RBM, in managing malaria research and resources.
5. HEALTH ECONOMY: Investigates the economic impact of malaria, the costs of anti-malarial drug development, and the role of regulatory agencies and the pharmaceutical industry in financing and accessibility.
6. DISCUSSION: Synthesizes the challenges of malaria in endemic countries, the role of national governments in taking ownership of malaria control, and the potential of PPPs to provide sustainable solutions.
7. CONCLUSION: Recommends streamlining global initiatives and fostering better organizational coordination to optimize resource allocation and effectively combat malaria resistance.
Keywords
Malaria, Plasmodium falciparum, Public-Private Partnerships (PPPs), Epidemiology, Drug resistance, Public Health, Global health, Insecticide-treated nets (ITNs), Antimalarial drugs, Disease control, Healthcare financing, Pharmaceutical industry, Pediatric malaria, Malaria in pregnancy.
Frequently Asked Questions
What is the primary focus of this thesis?
The work primarily addresses the global crisis of malaria in endemic countries, analyzing the scientific, economic, and institutional hurdles that prevent effective control and treatment.
What are the central themes discussed in the document?
Key themes include the biological aspects of the malaria parasite, the historical failure of eradication attempts, the shift toward sustainable control strategies, and the critical importance of collaborative partnerships between public and private sectors.
What is the central research goal?
The primary goal is to provide a comprehensive analysis of the malaria situation and to evaluate how multi-sectoral collaborations can improve the development, financing, and delivery of life-saving interventions in low-income settings.
Which scientific methodology is primarily employed?
The thesis utilizes a literature-based review and socio-economic analysis of existing public health data, treatment policies, and partnership models to draw its conclusions.
What topics are covered in the main section of the work?
The main part details the pathology of malaria, various preventive measures like vector control, specific treatment strategies including combination therapy, and the organizational framework provided by global actors like the WHO and various PPPs.
Which keywords define this work?
Key terms include malaria epidemiology, public-private partnerships, drug resistance, pharmaceutical industry economics, and malaria control in pediatric and pregnant populations.
Why are Public-Private Partnerships considered vital in this context?
PPPs are vital because they combine the resources, expertise, and infrastructure of global public organizations with the innovative and technical capabilities of the pharmaceutical industry to address neglected diseases where market incentives are historically weak.
What unique insights does the thesis provide regarding malaria in pregnant women?
The thesis highlights how pregnant women have been historically excluded from clinical trials and outlines the specific challenges and recommended strategies for protecting this highly vulnerable group through intermittent preventive treatments.
What does the thesis conclude about the Lapdap development project?
The thesis uses Lapdap as a case study to demonstrate that it is feasible to run a low-cost, effective development program through strategic cooperation between public entities and the private sector, serving as a model for future innovation in neglected diseases.
- Quote paper
- Petra Heyen (Author), 2004, The fight against Malaria in Malaria-Endemic Countries, Munich, GRIN Verlag, https://www.grin.com/document/37928
